Related Experiment Video

Updated: Jul 4, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.1K

ROR1 for Lymphoid Cancers

Stephen J Schuster1,2

  • 1Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.

NEJM Evidence
|February 6, 2024
PubMed

Insights

Zilovertamab vedotin, a new antibody-drug conjugate, shows promise in a phase 1 trial for relapsed or refractory mature B-cell malignancies. This research targets Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) in lymphoid cancers.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Mature B-cell malignancies represent a significant challenge in hematologic oncology, often necessitating novel therapeutic approaches for relapsed or refractory cases.
  • Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) is increasingly recognized as a promising therapeutic target in various B-cell cancers due to its role in tumor cell survival and proliferation.

Discussion:

  • This editorial reviews the first-in-human, phase 1 clinical trial evaluating zilovertamab vedotin, a novel antibody-drug conjugate targeting ROR1.
  • The trial assessed the safety, tolerability, and preliminary efficacy of zilovertamab vedotin in patients with relapsed or refractory mature B-cell malignancies.

Key Insights:

  • Zilovertamab vedotin demonstrated a manageable safety profile and preliminary signs of clinical activity in heavily pretreated patients.
  • The study provides crucial early data supporting the potential of ROR1-targeted antibody-drug conjugates in lymphoid cancers.

Outlook:

  • Further investigation in larger, randomized clinical trials is warranted to confirm the efficacy and optimal use of zilovertamab vedotin.
  • Targeting ROR1 represents a potential new avenue for treating aggressive B-cell lymphomas and leukemias, offering hope for patients with limited options.

More Related Videos

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model09:03

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model

Published on: October 16, 2017

8.8K
Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

5.1K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K